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PPAR α/δ agonist, insulin sensitizer, 
ameliorating hepatic inflammation, steatosis and 
fibrosis 
2 (11/2020)** NCT03883607 
 
Gemcabenea Dialkyl ether dicarboxylic acid with 
antihyperlipidemic activity 






Fatty acid metabolism key regulator, controlling 
the balance between de novo lipogenesis and 






Liraglutidea Glucagon-like peptide-1 analogue, injectable 
drug, with shown efficacy to induce weight loss 
and lower glucose in obese patients; approved 









Non-tumorigenic, engineered variant of 
fibroblast growth factor 21 (Receptors 1c, 4) 





Pioglitazonea PPARγ activator, attenuating IR, steatosis, 









Saroglitazara PPAR-α/γ dual agonist; approved for 













Selective PPAR-α modulator 2 (2/2020) NCT03350165 
 
BI 1467335b Promoter of leukocyte recruitment in the liver, 
with monoamine oxidase activity, insulin-like 
effects, and initiation of oxidative stress 




Selective non-bile acid FXR agonist, designed 







Emricasanb Irreversible pan-caspase inhibitor 2 (8/2019) NCT03205345 
 
Losartanb Angiotensin II receptor antagonist; approved for 
arterial hypertension 
2 (04/2020)** NCT03467217 
 
Metadoxineb Antioxidant, source of glutathione, capable of 
inhibiting adipocyte differentiation, limiting 
hepatic lipid accumulation and exerting 
antifibrotic properties 
4 (1/2020) NCT02051842 





A leukotriene receptor antagonist, which 
inhibits phosphodiesterase, 5-lipoxygenase and 
exhibits antifibrotic, anti-inflammatory activity 
in preclinical models 





Modulator of intestinal microbiome 1 (1/2021) NCT03803540 
 
IMM-124Ec IgG-rich extract from cows immunized against 
lipopolysaccharide, which reduces the hepatic 
exposure to gut-derived bacterial products 
2 (12/2019)** NCT03042767 
 
GR-MD-02d Galectin-3 inhibitor, resulting in improvement 
in liver histology with a significant reduction in 
NASH activity and collagen deposition 
2 (9/2016) NCT02421094 
 
* estimated date (month/year) of primary completion 
** pediatric clinical trial 
Categories: a. Liver steatosis, b. Oxidative stress/inflammation/ apoptosis, c. Gut microbiota, d. Anti-fibrotics 
Abbreviations: FXR; farnesoid X receptor, IR; insulin resistance, NAFLD; nonalcoholic fatty liver disease, 
NASH; nonalcoholic steatohepatitis, PPAR; peroxisome proliferator-activator receptors 
 
Table. A summary of selected ongoing clinical trials on pediatric NASH. Information has 
been retrieved by ClinicalTrials.gov as well as by the cited literature  
